Immune Checkpoint Therapies in Prostate Cancer
- PMID: 27111907
- PMCID: PMC4847149
- DOI: 10.1097/PPO.0000000000000176
Immune Checkpoint Therapies in Prostate Cancer
Abstract
Advanced prostate cancer is the second leading cause of death from cancer in the United States. In the era of cancer immunotherapy, it was the first malignancy to demonstrate improved survival with a cancer-specific vaccine, thus proving that prostate cancer is an immune-responsive disease. However, the success with immune checkpoint therapies in metastatic prostate cancer has been limited to date with only a subset of patients experiencing clinical benefit. The relative lack of response could be attributed to patient selection based on clinical attributes and the tumor microenvironment. Here, we review the current data on immune checkpoint therapies in prostate cancer and propose future directions.
Similar articles
-
Immune Checkpoint Therapy in Melanoma.Cancer J. 2016 Mar-Apr;22(2):73-80. doi: 10.1097/PPO.0000000000000183. Cancer J. 2016. PMID: 27111901 Review.
-
Immune Checkpoint Therapy in Head and Neck Cancers.Cancer J. 2016 Mar-Apr;22(2):108-16. doi: 10.1097/PPO.0000000000000180. Cancer J. 2016. PMID: 27111906 Review.
-
The State of Immune Checkpoint Inhibition in Urothelial Carcinoma: Current Evidence and Future Areas of Exploration.Cancer J. 2016 Mar-Apr;22(2):96-100. doi: 10.1097/PPO.0000000000000175. Cancer J. 2016. PMID: 27111904 Review.
-
Immunotherapy for the treatment of breast cancer: checkpoint blockade, cancer vaccines, and future directions in combination immunotherapy.Clin Adv Hematol Oncol. 2016 Nov;14(11):922-933. Clin Adv Hematol Oncol. 2016. PMID: 27930644 Review.
-
Immune Checkpoint Inhibitors in the Treatment of Gynecologic Malignancies.Cancer J. 2016 Mar-Apr;22(2):101-7. doi: 10.1097/PPO.0000000000000179. Cancer J. 2016. PMID: 27111905 Review.
Cited by
-
1,5-Disubstituted tetrazoles as PD-1/PD-L1 antagonists.RSC Med Chem. 2024 Feb 21;15(4):1210-1215. doi: 10.1039/d3md00746d. eCollection 2024 Apr 24. RSC Med Chem. 2024. PMID: 38665826 Free PMC article.
-
Prostate cancer research: tools, cell types, and molecular targets.Front Oncol. 2024 Mar 26;14:1321694. doi: 10.3389/fonc.2024.1321694. eCollection 2024. Front Oncol. 2024. PMID: 38595814 Free PMC article. Review.
-
A review of strategies to overcome immune resistance in the treatment of advanced prostate cancer.Cancer Drug Resist. 2023 Sep 25;6(3):656-673. doi: 10.20517/cdr.2023.48. eCollection 2023. Cancer Drug Resist. 2023. PMID: 37842236 Free PMC article. Review.
-
Novel Cellular and Immunotherapy: Toxicities and Perioperative Implications.Curr Oncol. 2023 Aug 16;30(8):7638-7653. doi: 10.3390/curroncol30080554. Curr Oncol. 2023. PMID: 37623035 Free PMC article. Review.
-
Prostate cancer cells synergistically defend against CD8+ T cells by secreting exosomal PD-L1.Cancer Med. 2023 Aug;12(15):16405-16415. doi: 10.1002/cam4.6275. Epub 2023 Jul 27. Cancer Med. 2023. PMID: 37501397 Free PMC article.
References
-
- el-Demiry MI, Hargreave TB, Busuttil A, et al. Lymphocyte sub-populations in the male genital tract. Br J Urol. 1985;57:769–74. - PubMed
-
- Chambers CA, Kuhns MS, Egen JG, et al. CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy. Annu Rev Immunol. 2001;19:565–94. - PubMed
-
- Walunas TL, Lenschow DJ, Bakker CY, et al. CTLA-4 can function as a negative regulator of T cell activation. Immunity. 1994;1:405–13. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical